172@29@17@249!~!172@29@0@53!~!|news|india|pan-india-covid-19-genome-studies-suggest-virus-genetically-stable-no-major-mutation-pmo-5976051.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to Moneycontrol Pro and get 365 bonus InterMiles! Use Code: INTERMILES
you are here: HomeNewsIndia
Last Updated : Oct 17, 2020 06:38 PM IST | Source: PTI

Pan-India COVID-19 genome studies suggest virus genetically stable, no major mutation: PMO

Mutation typically refers to the property of a virus to undergo changes when it multiplies and the virus may develop some new strains after it replicates.

PTI

As the work continues to develop an effective vaccine for COVID-19, the government on Saturday said two pan-India studies on the genome of the virus in India suggest it is genetically stable and has shown no major mutation. There had been concerns in some quarters that any major mutation detected in the novel coronavirus could hinder the development of an effective vaccine. However, some recent global studies have said the vaccines currently being developed for COVID-19 should not be affected by recent mutations.

Mutation typically refers to the property of a virus to undergo changes when it multiplies and the virus may develop some new strains after it replicates. In cases, the new strains tend to be less effective and therefore die out soon, while more powerful strains may lead to faster spread of the virus. After a review meeting chaired by Prime Minister Narendra Modi on the COVID-19 pandemic situation, and vaccine delivery, distribution and administration preparedness, the Prime Minister's Office said in a statement that three vaccines are in advanced stages of development in India, out of which two are in Phase II and one is in Phase-III.

The PMO further said, "Two pan-India studies on the Genome of SARS-CoV-2 (COVID-19 virus) in India conducted by ICMR and the Department of Biotechnology (DBT) suggest that the virus is genetically stable and there is no major mutation in the virus." Last month, Union Health Minister Harsh Vardhan had said no significant or drastic mutations have been found in strains of SARS-CoV-2 in India till now.

Close

He had also said the ICMR (Indian Council of Medical Research) was conducting large-scale sequencing of nationally representative strains collected over a few months and detailed results on mutations of the virus will be available in early October. Replying to a query on mutations of SARS-COV2, ICMR Director-General Dr Balram Bhargava had said at a press briefing earlier this week that minor changes called "drifts" may happen from time to time, but major genetic mutations of viruses or "shifts" may happen in about a decade or two.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

In this context, the effectiveness of a vaccine will not be determined by minor "drifts", he had said. A study by a group of researchers last month found that the coronavirus genomes in India have 5.39 percent mutation similarity with 72 nations.

Mutations in an organism's genetic material are natural 'errors' in the cell replication process that may give the virus new 'powers' of survival, infectivity, and virulence. It can affect the ability of vaccines and drugs to bind the virus or to create a specific immune response against it. The study also revealed that the US, the UK and India are the top three nations with a geometric mean of 3.27 percent, 3.59 percent, and 5.39 percent, respectively, of mutation similarity score with other 72 countries.

Indrajit Saha, an assistant professor in the Department of Computer Science and Engineering of National Institute of Technical Teachers' Training and Research, Kolkata, and his team have also developed a web-based COVID-Predictor to predict the sequence of viruses online on the basis of machine learning. The PMO statement said a National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) in consultation with state governments and all relevant stakeholders have prepared a detailed blueprint of vaccine storage, distribution, and administration.

The Expert Group, in consultation with states, is working actively on prioritisation and distribution of vaccines. At the meeting, the prime minister directed that keeping in view the geographical span and diversity of the country, the access to the vaccine should be ensured speedily.

Modi stressed that every step in the logistics, delivery, and administration should be put in place rigorously and it must include advanced planning of cold storage chains, distribution network, monitoring mechanism, advance assessment, and preparation of ancillary equipment required, such as vails, syringes, etc.
First Published on Oct 17, 2020 06:38 pm
Sections